Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

Summary

An immunotherapy study combining ipilimumab and evofosfamide for the treatment of patients with confirmed metastatic or locally advanced prostate cancer, metastatic pancreatic cancer, melanoma or human papillomavirus (HPV) negative squamous cell carcinoma of head and neck that have failed to respond to standard therapy, progressed despite standard therapy, for which standard therapy does not offer the potential for increased survival.

Timeline

Start

2017-05-10

Primary completion

2019-01

Completion

2019-04

Drugs

Indications